ModernGraham Valuation

Company Name:

Edwards Lifesciences Corp



Company Ticker Date of Analysis

9/11/2015

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

,		
1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$14,980,429,343 Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	5.16 Pass
3. Earnings Stability	Positive EPS for 10 years prior	Pass
4. Dividend Record	Dividend Payments for 10 years prior	Fail
	Increase of 33% in EPS in past 10 years using 3 year averages at	
5. Earnings Growth	beginning and end	387.66% Pass
6. Moderate PEmg Ratio	PEmg < 20	30.81 Fail
7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	6.68 Fail

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

Sufficiently Strong Financial Condition	Current Ratio > 1.5	5.16 Pass
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	0.32 Pass
3. Earnings Stability	Positive EPS for 5 years prior	Pass
4. Dividend Record	Currently Pays Dividend	Fail
5. Earnings Growth	EPSmg greater than 5 years ago	Pass

Suitability

Defensive Enterprising Yes

Stage 2: Determination of Intrinsic Value

EPSmg	\$4.51
MG Growth Estimate	15.00%
MG Value	\$173.71
MG Value based on 3% Growth	\$65.42
MG Value based on 0% Growth	\$38.35
Market Implied Growth Rate	11.16%

MG Opinion

Current Price \$139.02 % of Intrinsic Value 80.03%

Opinion **Fairly Valued**


Stage 3: Information for Further Research


Net Current Asset Value (NCAV)	\$8.88
Graham Number	\$44.34
PEmg	30.81
Current Ratio	5.16
PB Ratio	6.68
Dividend Yield	0.00%
Number of Consecutive Years of Dividend Growth	0

Useful Links: ModernGraham tagged articles

Morningstar Google Finance MSN Money Yahoo Finance Seeking Alpha GuruFocus SEC Filings

EPS History		EPSmg History		
Next Fiscal Year Estimate	\$4.10	Next Fiscal Year Estimate		\$4.51
Dec14	\$7.48	Dec14		\$4.29
Dec13	\$3.44	Dec13		\$2.58
Dec12	\$2.48	Dec12		\$2.05
Dec11	\$1.98	Dec11		\$1.75
Dec10	\$1.83	Dec10		\$1.54
Dec09	\$1.95	Dec09		\$1.31
Dec08	\$1.10	Dec08		\$0.91
Dec07	\$0.94	Dec07		\$0.76
Dec06	\$1.05	Dec06		\$0.64
Dec05	\$0.64	Dec05		\$0.40
Dec04	\$0.02	Dec04		\$0.10
Dec03	\$0.65	Dec03		\$0.00
Dec02	\$0.46	Dec02		-\$0.35
Dec01	-\$0.10	Dec01		-\$0.67
Dec00	-\$2.41	Dec00		-\$0.80
Dec99	\$0.00	Dec99		\$0.00
Dec98	\$0.00	Balance Sheet Information	Jun15	
Dec97	\$0.00	Total Current Assets		\$2,297,000,000
Dec96	\$0.00	Total Current Liabilities		\$445,200,000
Dec95	\$0.00	Long-Term Debt		\$600,300,000
		Total Assets		\$3,608,300,000
		Intangible Assets		\$389,800,000
		Total Liabilities		\$1,319,700,000
		Shares Outstanding (Diluted Average)		110.000.000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company The Best Companies of the Medical Industry – June 2015

The 6 Best Stocks For Value Investors This Week – 6/13/15

Edwards Lifesciences Corporation Analysis - June 2015 Update \$EW

18 Companies in the Spotlight This Week – 3/15/15

Edwards Lifesciences Corporation Quarterly Valuation – March 2015 \$EW

Other ModernGraham posts about related companies

Cerner Corporation Analysis – September 2015 Update \$CERN

Boston Scientific Inc. Analysis – September 2015 Update \$BSX

Intuitive Surgical Inc. Analysis – September 2015 Update \$ISRG

Dentsply International Inc. Analysis – August 2015 Update \$XRAY

Becton Dickinson & Company Analysis – August 2015 Update \$BDX

Align Technology Analysis – Initial Coverage \$ALGN

Varian Medical Systems Inc Analysis – August 2015 Update \$VAR

Psychemedics Corporation Analysis – August 2015 Update \$PMD

C.R. Bard Inc. Analysis – August 2015 Update \$BCR

Thermo Fisher Scientific Inc. Analysis – 2015 Update \$TMO